Salah Nabhan
About Salah Nabhan
Salah Nabhan is a Senior Director of Clinical Operations at MOMA Therapeutics, with extensive experience in clinical trial management and operations across various organizations, including Agios Pharmaceuticals and Sarah Cannon Research Institute.
Current Role at MOMA Therapeutics
Salah Nabhan serves as the Senior Director of Clinical Operations at MOMA Therapeutics. He has held this position since 2023, contributing to the company's clinical strategy and operations. His role involves overseeing clinical trials and ensuring compliance with regulatory standards. His extensive background in clinical operations supports MOMA Therapeutics' mission to advance innovative therapies.
Previous Experience at Agios Pharmaceuticals
Salah Nabhan worked at Agios Pharmaceuticals in various capacities. He served as a Clinical Trial Manager from 2014 to 2017, where he managed multiple clinical trials. He then advanced to Senior Clinical Trial Manager from 2017 to 2019, focusing on operational aspects of clinical studies. His final role at Agios was as Associate Director of Clinical Operations in Early Oncology Development for six months in 2020.
Experience at Sarah Cannon Research Institute
At Sarah Cannon Research Institute, Salah Nabhan held two positions. He was the Lead Clinical Trial Specialist from 2011 to 2014, managing clinical trials within the Sarah Cannon Center for Blood Cancers. Prior to that, he worked as a Clinical Trial Specialist in the Drug Development Unit from 2009 to 2011, contributing to the development and execution of clinical protocols.
Education and Academic Background
Salah Nabhan earned a Bachelor of Science (B.S.) in Biology from the University of Arkansas, studying from 2004 to 2006. He furthered his education at the same institution, obtaining a Master of Science (M.S.) in Molecular Genetics and Pharmacology from 2007 to 2009. His academic background provides a strong foundation for his career in clinical operations.
Experience at Foghorn Therapeutics, Inc.
Salah Nabhan served as the Director of Clinical Operations at Foghorn Therapeutics, Inc. from 2021 to 2023. In this role, he was responsible for overseeing clinical development strategies and managing clinical trial operations, contributing to the advancement of the company's therapeutic pipeline.